Alogliptin: a new addition to the class of DPP-4 inhibitors

Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibitio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Radha Andukuri, Andjela Drincic, Marc Rendell
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/3735030292114be3af9d5fe5b144b38a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3735030292114be3af9d5fe5b144b38a
record_format	dspace
spelling	oai:doaj.org-article:3735030292114be3af9d5fe5b144b38a2021-12-02T00:19:31ZAlogliptin: a new addition to the class of DPP-4 inhibitors1178-7007https://doaj.org/article/3735030292114be3af9d5fe5b144b38a2009-07-01T00:00:00Zhttp://www.dovepress.com/alogliptin-a-new-addition-to-the-class-of-dpp-4-inhibitors-a3367https://doaj.org/toc/1178-7007Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation.Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors.Methods: A comprehensive literature search was performed using the term &lsquo;alogliptin&rsquo;. Original research articles and review articles as well as scientific abstracts were included. Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 0.5% to 0.6%. Combination therapy yielded similar reductions (&minus;0.5% with metformin, &minus;0.6% with glyburide, &minus;0.8% with pioglitazone and &ndash;0.6% with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus.Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.Keywords: alogliptin, DPP-4 inhibitors, GLP-1, vildagliptin, sitagliptin, saxagliptin Radha AndukuriAndjela DrincicMarc RendellDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 117-126 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Radha Andukuri Andjela Drincic Marc Rendell Alogliptin: a new addition to the class of DPP-4 inhibitors
description	Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation.Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors.Methods: A comprehensive literature search was performed using the term &lsquo;alogliptin&rsquo;. Original research articles and review articles as well as scientific abstracts were included. Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 0.5% to 0.6%. Combination therapy yielded similar reductions (&minus;0.5% with metformin, &minus;0.6% with glyburide, &minus;0.8% with pioglitazone and &ndash;0.6% with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus.Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.Keywords: alogliptin, DPP-4 inhibitors, GLP-1, vildagliptin, sitagliptin, saxagliptin
format	article
author	Radha Andukuri Andjela Drincic Marc Rendell
author_facet	Radha Andukuri Andjela Drincic Marc Rendell
author_sort	Radha Andukuri
title	Alogliptin: a new addition to the class of DPP-4 inhibitors
title_short	Alogliptin: a new addition to the class of DPP-4 inhibitors
title_full	Alogliptin: a new addition to the class of DPP-4 inhibitors
title_fullStr	Alogliptin: a new addition to the class of DPP-4 inhibitors
title_full_unstemmed	Alogliptin: a new addition to the class of DPP-4 inhibitors
title_sort	alogliptin: a new addition to the class of dpp-4 inhibitors
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/3735030292114be3af9d5fe5b144b38a
work_keys_str_mv	AT radhaandukuri alogliptinanewadditiontotheclassofdpp4inhibitors AT andjeladrincic alogliptinanewadditiontotheclassofdpp4inhibitors AT marcrendell alogliptinanewadditiontotheclassofdpp4inhibitors
_version_	1718403793506271232

Alogliptin: a new addition to the class of DPP-4 inhibitors

Ejemplares similares